Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID). Understanding the inherent immune dysregulation of these diseases as well as the additional disruption that comes as a result of IMID treatments has been important during the COVID-19 pandemic. With vaccines becoming widely available, dermatologists need to be familiar with the risks and benefits of vaccination in these patients, particularly those taking biologics, in order to have informed discussions with their patients. In this review, we present the current evidence related to COVID-19 vaccine safety and efficacy in patients with IMID and review existing recommendations for vaccination against SARS-CoV-2.

Given the current evidence, there is minimal concern that these patients are at any greater risk of harm from COVID-19 vaccination compared to healthy controls. For most, the benefit of avoiding severe COVID-19 through vaccination will outweigh the theoretical risk of these vaccines. A question that is still outstanding is whether patients on biologics will generate a sufficient immune response to the vaccine, which may be dependent on the specific biologic therapy and indication being treated. This underscores the importance of following patients with IMID after vaccination to determine the safety, efficacy, and duration of the vaccine in this population.

皮肤科医生诊断和治疗许多免疫介导的炎症性疾病 (IMID)。在 COVID-19 大流行期间，了解这些疾病固有的免疫失调以及 IMID 治疗带来的额外破坏非常重要。随着疫苗的普及，皮肤科医生需要熟悉这些患者接种疫苗的风险和益处，尤其是那些服用生物制剂的患者，以便与患者进行知情讨论。在这篇综述中，我们提出了与 IMID 患者 COVID-19 疫苗安全性和有效性相关的当前证据，并回顾了针对 SARS-CoV-2 疫苗接种的现有建议。

鉴于目前的证据，与健康对照组相比，这些患者因 COVID-19 疫苗接种而受到伤害的风险更大，这一点几乎没有人担心。对于大多数人来说，通过接种疫苗避免严重的 COVID-19 的好处将超过这些疫苗的理论风险。一个仍然悬而未决的问题是，使用生物制剂的患者是否会对疫苗产生足够的免疫反应，这可能取决于具体的生物疗法和所治疗的适应症。这强调了在接种疫苗后跟踪 IMID 患者以确定疫苗在该人群中的安全性、有效性和持续时间的重要性。